{
  "$schema": "https://themachinepress.com/schemas/story-v1.schema.json",
  "schema_version": "1.0.0",
  "document_type": "machine_press_story",
  "story": {
    "story_id": "mp-2026-08-01-017",
    "source_story_id": "tmp-sidebar-daraxonrasib-pancreatic-trial",
    "edition_id": "mp-2026-08-01-morning-0023",
    "edition_url": "https://themachinepress.com/edition/2026-08-01",
    "position": 19,
    "story_type": "ticker",
    "section": "research",
    "editorial_classification": "editorial",
    "headline": "A RAS Inhibitor Extended Survival in an Eligible Pancreatic-Cancer Trial Group",
    "slug": "a-ras-inhibitor-extended-survival-in-an-eligible-pancreatic-cancer-trial-group",
    "dek": "An institutional overview reports a median-survival gain for daraxonrasib after chemotherapy stopped working.",
    "summary": "An institutional overview reports a median-survival gain for daraxonrasib after chemotherapy stopped working.",
    "body_text": "A Johns Hopkins Kimmel Cancer Center overview says a trial of the once-daily RAS(ON) inhibitor daraxonrasib reported median survival of 13.2 months, versus 6.7 months in the comparison context, for eligible patients with metastatic pancreatic ductal adenocarcinoma after chemotherapy stopped working. The drug is investigational, and the result does not apply to every pancreatic-cancer patient.",
    "why_it_matters": "An institutional overview reports a median-survival gain for daraxonrasib after chemotherapy stopped working.",
    "limitations": [
      "The drug is investigational, and the result does not apply to every pancreatic-cancer patient."
    ],
    "importance": 8,
    "canonical_url": "https://themachinepress.com/story/mp-2026-08-01-017/a-ras-inhibitor-extended-survival-in-an-eligible-pancreatic-cancer-trial-group",
    "json_url": "https://themachinepress.com/story/mp-2026-08-01-017.json",
    "first_published_at": "2026-08-01T09:00:00.000-04:00",
    "modified_at": "2026-08-01T09:00:00.000-04:00",
    "content_status": "new",
    "is_carryover": false,
    "carryover_reason": null,
    "key_claims": [
      {
        "claim_id": "claim-mp-2026-08-01-017-001",
        "text": "An institutional overview reports a median-survival gain for daraxonrasib after chemotherapy stopped working.",
        "source_ids": [
          "source-2026-08-01-019"
        ],
        "qualification": "The drug is investigational, and the result does not apply to every pancreatic-cancer patient."
      }
    ],
    "source_ids": [
      "source-2026-08-01-019"
    ],
    "tags": [
      "pancreatic cancer",
      "daraxonrasib",
      "RAS inhibitor",
      "clinical trial"
    ],
    "image_url": null,
    "corrections": []
  },
  "sources": [
    {
      "source_id": "source-2026-08-01-019",
      "title": "Johns Hopkins Kimmel Cancer Center via Newswise: Daraxonrasib trial overview",
      "publisher": "Johns Hopkins Kimmel Cancer Center via Newswise",
      "url": "https://www.newswise.com/articles/new-drug-could-double-survival-for-eligible-patients-with-pancreatic-cancer",
      "canonical_url": "https://www.newswise.com/articles/new-drug-could-double-survival-for-eligible-patients-with-pancreatic-cancer",
      "source_type": "secondary_reporting",
      "is_primary_source": false,
      "published_at": null,
      "accessed_at": "2026-08-01T08:36:00.000-04:00",
      "supports_claim_ids": [
        "claim-mp-2026-08-01-017-001"
      ]
    }
  ],
  "corrections": [],
  "publisher": {
    "name": "The Machine Press",
    "url": "https://themachinepress.com",
    "description": "A daily newspaper for the age of artificial intelligence."
  },
  "cite_this_report": {
    "title": "A RAS Inhibitor Extended Survival in an Eligible Pancreatic-Cancer Trial Group",
    "publisher": "The Machine Press",
    "published_at": "2026-08-01T09:00:00.000-04:00",
    "canonical_url": "https://themachinepress.com/story/mp-2026-08-01-017/a-ras-inhibitor-extended-survival-in-an-eligible-pancreatic-cancer-trial-group"
  }
}